Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): a randomised, open-label, multicentre, phase 3 trial

Phase 3, 660 transplant-eligible NDMM patients (331 Isa-VRd, 329 VRd) in Germany. MRD negativity after induction (ITT) was reached in 166 (50%) vs 117 (36%) (OR 1.82, 95% CI 1.33-2.48; p=0.00017). Grade 3-4 neutropenia 23% vs 7%. MRD analysis of an RCT (level 2), not MRD-guided therapy. NCT03617731.

Lancet HaematolPubMed 36328040